UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

o

Rule 13d-1(b)

x

Rule 13d-1(c)

o

Rule 13d-1(d)

CUSIP No. 90238J103

1.

Names of Reporting Persons.
Eagle Pharmaceuticals, Inc.

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

o

(b)

o

3.

SEC Use Only

4.

Citizenship or Place of Organization
Delaware

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With:

5.

Sole Voting Power
10,000,000 shares(1)

6.

Shared Voting Power
0

7.

Sole Dispositive Power
10,000,000 shares(1)

8.

Shared Dispositive Power
0

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
10,000,000

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

11.

Percent of Class Represented by Amount in Row (9)
8.2%(2)

12.

Type of Reporting Person (See Instructions)
CO

CUSIP No. 90238J103

Item 1.

(a)

Name of Issuer:
Tyme Technologies, Inc.

(b)

Address of Issuer’s Principal Executive Offices:
17 State Street, 7th Floor

New York, NY 10004

Item 2.

(a)

Name of Person Filing:
Eagle Pharmaceuticals, Inc.

(b)

Address of Principal Business Office or, if none, Residence:
50 Tice Boulevard, Suite 315

Woodcliff Lake, NJ 07677

(c)

Citizenship:
Delaware

(d)

Title of Class of Securities:
Common Stock, $0.0001 par value per share

(e)

CUSIP Number:
90238J103

Item 3.

If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

(a)

o

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b)

o

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c)

o

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d)

o

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e)

o

An investment advisor in accordance with §240.13d-1(b)(1)(ii)(E);

(f)

o

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)

o

A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)

o

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

o

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

o

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); or

(k)

o

Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

CUSIP No. 90238J103

Item 4.

Ownership.

The following information with respect to the ownership of the Common Stock of the Issuer by the Reporting Person is provided as of January 7, 2020:

(a)

Amount beneficially owned   

See Row 9 of cover page.

(b)

Percent of class:   

See Row 11 of cover page.

(c)

Number of shares as to which such person has:

(i)

Sole power to vote or to direct the vote   

See Row 5 of cover page.

(ii)

Shared power to vote or to direct the vote    

See Row 6 of cover page.

(iii)

Sole power to dispose or to direct the disposition of   

See Row 7 of cover page.

(iv)

Shared power to dispose or to direct the disposition of   

See Row 8 of cover page.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following o.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

CUSIP No. 90238J103

Item 10.

Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

Eagle Pharmaceuticals, Inc.

Date: January 17, 2020

/s/ Scott Tarriff

Scott Tarriff

Chief Executive Officer